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The absolute stereochemistry of chiral drugs is usually established via X-ray crystallography. However,
vibrational circular dichroism (VCD) spectroscopy coupled with quantum mechanics simulations offers
a rapid alternative to crystallography and is readily applied to both crystalline and non-crystalline sam-
ples. VCD is an effective complement to X-ray analysis of drug candidates, and it can be used as a high-
throughput means of assessing absolute stereochemistry at all phases of the discovery process (hundreds
of assignments per year). The practical implementation (or fee-for-service outsourcing) of VCD and
selected case studies are illustrated with an emphasis on providing utility and impact to pharmaceutical
discovery programs.
 2013 Elsevier Ltd. All rights reserved.ntin)Nearly two out of three drugs reaching the commercial market
are chiral, and the determination of absolute stereochemistry is a
central component of their discovery and development (Fig. 1).1
Frequently, the absolute conﬁguration of a chiral drug is not known
until relatively late in the discovery phase, and most often the
structure is determined using the accepted gold standard of X-
ray crystallography and/or the sample is prepared using a stereo-
controlled synthetic route. However, vibrational circular dichroism
(VCD) spectroscopy offers a rapid alternative to crystallography
and is readily applied to both crystalline and non-crystalline sam-
ples at all phases of the discovery process. This Digest provides to a
medicinal chemistry audience an overview of the essentials of VCD
as an emerging technology in pharmaceutical research as well as
several case studies of practical examples that have impacted drug
discovery programs.
A VCD spectrum is deﬁned as the differential absorbance of left-
vs. right-circularly polarized infrared light by a chiral sample:
VCD spectrum : DAðmÞ ¼ AleftðmÞ  Aright
Like electronic (UV/visible) circular dichroism spectroscopy
familiar to chemists, VCD spectra of pure enantiomeric species
are identical in all respects, except that the spectral features ofthe two enantiomers will be opposite in sign, that is, if a band is
positive for one enantiomer, it will be negative for the opposite
enantiomer (Fig. 2).
Relative to CD analysis, VCD has the technical challenge of lim-
ited sensitivity, but offers the beneﬁt of numerous, well-deﬁned
bands with which to assign the absolute conﬁguration. Analogousvix)
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Figure 2. VCD spectra for an enantiomeric pair. The blue spectrum of one
enantiomer is the opposite of the red spectrum of the other enantiomer. Because
the spectrum is collected in the ﬁngerprint region of the IR, the number of peaks
(i.e., the information density) is generally greater than that of electronic CD spectra.
4020 S. S. Wesolowski, D. E. Pivonka / Bioorg. Med. Chem. Lett. 23 (2013) 4019–4025to the ﬁngerprint region of classical IR spectra, VCD spectra typi-
cally provide information-dense patterns due to the differential
absorbance associated with speciﬁc vibrational modes, most often
those in close proximity to a chiral center.
While the raw VCD spectra can be used to differentiate two
enantiomers (or more complex molecules with multiple chiral
centers), the experimental spectra alone are not indepen-
dently sufﬁcient to assign absolute chirality. Absolute assignment
requires comparison of the VCD spectrum to a reference spec-
trum for which the speciﬁc signs of bands are known to be di-
rectly linked to an established absolute chirality. While such a
reference spectrum can be obtained from a compound for which
the absolute chiral structure is known (i.e., either through X-ray
crystal structure analysis or from a batch generated through a
stereo-speciﬁc synthesis), most often no such prior compound
or knowledge is available. In these cases the reference spec-
trum must be obtained from quantum mechanics simulations of
the VCD spectrum (most often using density functional the-
ory).2–5Figure 3. The essential steps in the VCD assignment of a single enantiomer sample of
requires collection of IR spectra using left- and right-circularly polarized light and gen
constructed using quantummechanics (QM) simulations and subsequent Boltzmann weig
lying conformers. Direct comparison of the measured and simulated VCD spectra facilitate
the simulated S spectrum).Figure 3 summarizes the fundamental steps involved in VCD
chiral assignment and also provides data for our ﬁrst case study.
For experimental VCD acquisition, typically ca. 2–10 mgs of mate-
rial is sufﬁcient to achieve a suitable signal. Neutral compounds
(rather than salts) are desirable to avoid the need to model com-
plex matrix and counter-ion effects. Ideally, samples are dissolved
in a nonpolar solvent (e.g., CDCl3) to minimize the effects of hydro-
gen bonding and leave the physical system with minimal perturba-
tions such that the environment of the simulations more
accurately mimics the conditions in the experimental cell. A num-
ber of more technically detailed overviews of VCD are also avail-
able in the literature6–8 as well as a recent book speciﬁcally
aimed toward organic chemists.9
The number of VCD assignments of absolute stereochemistry is
estimated to be in the thousands.10 These chiral assignments fall
into three general categories:
1. Assignment of compounds for which chemists had no precon-
ceived notion of the absolute stereochemistry.
2. Conﬁrmation of the stereochemistry already established (or at
least inferred or suspected) by the chemists.
3. Revelation that the absolute stereochemistry is not what the
chemists anticipated.
All three scenarios have value, although the last is arguably the
most intriguing.
Case study #1: neurokinin-3 antagonists and intermediates.
Neurokinin-3 (NK3) antagonists have been pursued for CNS
indications including schizophrenia and pain, and also for potential
utility in androgen-dependent diseases.11–14 The NK3 program at
AstraZeneca yielded AZD2624 which contains a chiral amide sub-
stituent (Fig. 4).15 Since the complexity of the VCD simulations in-unknown absolute stereochemistry. The acquisition of a measured VCD spectrum
erating the difference spectrum. Simulated spectra of the R and S enantiomers are
hted co-addition of Lorentzian-broadened rotational strengths of energetically low-
s assignment, in this case a match to the simulated R spectrum (and opposite that of
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Figure 4. NK3 antagonist AZD2624. VCD assignment of the much smaller chiral
amine intermediate is a practical strategy for assignment (by inference) of the ﬁnal
compound. This strategy requires that the stereocenter is unaffected by subsequent
synthetic steps following its installation.
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many more conformers), a practical option is to assign the chirality
of intermediates whenever possible.
While efﬁcient, the strategy of assigning chiral intermediates
relies on the integrity of the chiral center being unaltered in any
subsequent chemical transformations and must be used with
this qualiﬁcation clearly in mind. A portion of one synthetic
route for a related series of sulfoxide NK3 antagonists is shown
in Figure 5.16 The ﬁnal compounds in this sub-series contain
two chiral centers: the amide substituent and the sulfoxide.
The amine intermediates that were separated by chiral
chromatography were assigned by VCD, and the SAR of this ser-
ies could then be assessed with full knowledge of the amide
stereochemistry.
The chiral assignment of these small amines is straightforward
and unambiguous as shown in Figure 3. Clearly, the measured
cyclopropyl amine in this case can be assigned as the S conﬁgura-
tion by comparison to the simulated spectra. The turnaround time
for assignment of compounds of this size can be as short as a single
day. For key compounds, the more complex assignment of both
stereocenters was performed on each ﬁnal product. While unam-
biguous assignments are often possible for complex compounds
with multiple stereocenters, careful selection and Boltzmann
weighting of the relevant conformers in the simulated spectra
are essential. Quite often, the most practical and cost-effectiveN
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Figure 5. Example synthetic route of NK3 antagonists (see Ref. 16): (a) amine, EDCI,
HOBt, DIPEA, DCM; (b) NaIO4, MeOH/H2O, The VCD assignment of a variety of chiral
amines (e.g., cyclopropyl analog in Fig. 3) allows the selection of the desired chiral
amine in step (a) and the assignment of this stereocenter in the ﬁnal product. For
key compounds, the absolute conﬁguration (both the amide portion and the
sulfoxide chirality) was determined for the ﬁnal product by comparing measured
spectra to all four possible simulated spectra (R,R; S,S; R,S; S,R) and ultimately
conﬁrmed by X-ray crystallography.chiral assignments for a series of compounds can be realized by
characterizing the smallest and least conformationally ﬂexible
intermediate that has the stereocenter installed (provided that it
is assured to be retained in subsequent steps). For key compounds,
assessment of the ﬁnal compound is always advisable.
Case study #2: re-assignment of chirality of a histamine-3 tool
compound.
Since the discovery of the histamine-3 (H3) receptor in 198317
and its subsequent cloning in 1999,18 H3 antagonists and inverse
agonists have been sought for indications ranging from cognitive
deﬁcits in Alzheimer’s disease to Tourette syndrome, with a num-
ber of compounds currently in clinical trials.19,20 One of the ﬁrst
tool compounds used widely in H3 pharmaceutical research is cip-
ralisant, aka Gliatech’s GT-2331 (Fig. 6).21 The structure of ciprali-
sant was published as the dextrorotatory (+) enantiomer with
(1R,2R) absolute stereochemistry assigned by X-ray crystallogra-
phy based on a sultam derivative.22,23 Later, Liu et al. at Abbott pre-
pared cipralisant and described a large scale synthesis of this
important reference compound.24 Additionally, their X-ray crystal-
lography of the sultam intermediate as well as the L-tartrate and
D-tartrate salts of cipralisant itself suggest that while the more bio-
logically active enantiomer is the dextrorotatory (+) enantiomer,
its true absolute stereochemistry is instead (1S,2S).
Minick et al. at GSK played the additional role of arbiter using
VCD as an independent method for determining the absolute
conﬁguration of cipralisant.25 Their thorough investigation of
the imidazole tautomeric states and hydrogen bonded dimers
provided conclusive and independent evidence for cipralisant
having (1S,2S) absolute stereochemistry. It represents a classic
case of working through the additional complexities of simulat-
ing key elements of the physical system in solution (tautomeric
state, interactions in solution, etc.) that are sometimes required
to achieve a reliable match between simulated and measured
spectra, that is, it is not always a turn-key technique. It also re-
minds us that while X-ray crystallography remains the gold stan-
dard for chiral determination, it too relies upon ﬁtting scattering
data and involves human handling, and it is not absolutely
failsafe.
Case study #3: unanticipated effect of substituents in NMDA SAR.
N-Methyl-D-aspartic acid (NMDA) antagonists have received a
resurgence of attention, particularly as compounds are tested in
clinical trials following the discovery that ketamine can have
fast-acting antidepressant effects.26 One example of an NMDA
antagonist is AstraZeneca’s AZD6765 which has an established S
absolute stereochemistry determined by X-ray crystallography of
the dihydrochloride salt. The S enantiomer of AZD6765 binds more
strongly to the target than the R enantiomer.HN
N
H
H
HN
N
H
H
(1R,2R)
originally reported
(1S,2S)
reassigned by X-ray and VCD
Reassignment of stereochemistry of
H3 ligand cipralisant
Figure 6. Structure of the H3 ligand cipralisant. The stereochemistry was reas-
signed based on separate X-ray analyses at Abbott (Ref. 24) and VCD analysis at GSK
(Ref. 25).
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Figure 8. Structures of AZD6765 and 1. While the compounds have ‘opposite’
stereochemistry, Cahn-Ingold-Prelog priority rules dictate that both compounds are
named with the S designation.
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pound 1 shows unambiguously that the stereochemistry of the
enantiomer with greater afﬁnity to the target is not the same as
that of AZD6765 (NH2 into the plane versus out of the plane, see
Figs 7 and 8). The experimental VCD spectrum of 1 (purple spec-
trum) matches the simulated VCD spectrum with the NH2 group
pointed into the plane as drawn (green spectrum) and is opposite
that of the simulated VCD spectrum with the NH2 group out of the
plane (red spectrum).
During lead optimization, it is quite useful to have rapid abso-
lute stereochemical assignment, particularly if one enantiomer is
not consistently the more active enantiomer within a series. In
such cases, clear assignment of the absolute stereochemistry pro-
vides direct interpretation of SAR and avoids assumptions about
the biological activity associated with each enantiomer. It also
eliminates the ambiguity of using elution order from chiral chro-
matography (or other empirical observations) as a surrogate for
tentative chiral assignment and SAR interpretation. There is no
heavy atom in the ligand (i.e., a sulfur atom or larger), and standard
X-ray crystallography is reliant upon use of a heavy-atom salt,
although more sophisticated analyses are possible without this
requirement.27 VCD assignments, however, do not require crystals
at all and could be performed shortly after synthesis of compounds
in this series. In this case, the unanticipated stereochemical ﬁnding
for 1 was determined by VCD and later conﬁrmed by crystallo-
graphic studies on salts. Interestingly, nomenclature rules dictateFigure 7. Chiral assignment of the gem-dimethyl compound 1 (more active enantiomer).
spectrum with the NH2 group pointed into the plane as drawn (green spectrum) and is op
spectrum). Note the comparison of absolute stereochemistry assignment to AZD6765 wh
computed spectra at the 6-311++G⁄⁄/B3PW91 level of theory.that the more active enantiomer for both AZD6765 and 1 are
named with the S designation even though they have the ‘opposite’
stereochemistry (Fig. 8).
Additional examples. VCD assignments are becoming part of the
organic and medicinal chemistry mainstream as evidenced by the
growing number of examples in the literature. Figure 9 provides
only a sampling of additional examples that demonstrate the types
of compounds and applications that are possible (e.g., assignment
of GABA modulators that exhibit atropisomers with axial chiral-
ity).28–34
Advances in VCD instrumentation and software. We have written
an extensive in-house program under a single platform that serves
as the launch point for unattended sample acquisition and genera-
tion of simulated spectra as well as the conduit to visualization and
interpretation tools. This has been critical for the efﬁcient (essen-
tially unattended) acquisition and simulation of spectra. As impor-
tant, the instrumentation and detection advances (even within a
two year span) are exempliﬁed in Figure 10. A series of mGluR2 po-
sitive allosteric modulators that required 25 mgs of sample to
achieve sufﬁcient signal for chiral assignment in our ﬁrst efforts
in VCD needed only 2 mgs to achieve comparable signal using a
modiﬁed system. Reducing the sample requirement to a few milli-The experimental VCD spectrum of 1 (purple spectrum) matches the simulated VCD
posite that of the simulated VCD spectrum with the NH2 group out of the plane (red
ich has the NH2 pointed out of the plane as drawn (see Fig. 8). The simulations used
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Figure 9. Additional examples of VCD assignments spanning several therapeutic areas. Examples of atropisomer assignment as well as examples of stereochemistry re-
assignment based on VCD analyses are included.
Figure 10. The practical impact of advances in VCD hardware. The entry-level technology in 2007 could require as much as 25 mgs of sample to achieve suitable signal-to-
noise ratios. Incorporation of customized robotics, 48 h detector and rebuilt signal ampliﬁers provides signiﬁcant enhancement of sensitivity and facilitates unattended
sampling. In this chemical series, the sample requirement was reduced 10-fold to ca. 2 mgs while retaining sufﬁcient signal for matching the computed spectrum.
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usage within an active discovery program where ﬁrst-synthesized
batches may be of a limited quantity and have biological and
ADME screens as a higher priority.
Likewise, quantum chemistry packages have become faster and
more robust.35,36 While more rigorous QM methods (e.g., coupled-
cluster theory) are still too computationally intensive for most
drug-like compounds, density functional theory (DFT) has beenremarkably accurate for chiral assignment.7 Furthermore, mole-
cules even larger and more ﬂexible than those shown in Figure 9
may often be assigned by measuring the VCD spectrum of the full
molecule, but matching to a truncated model system for the DFT
simulations where parts of the molecule far from the chiral center
(and thus are unlikely to contribute signiﬁcantly to the VCD signal)
are deleted. In addition to computational speed, developments
in commercial software over the next decade will likely include
Figure 11. Schematic of the correlation analysis of the measured rotational strengths (proportional to VCD intensity) and the Boltzmann-weighted computed rotational
strengths for each enantiomer advanced by Stephens et al. (for example in Ref. 28). The match of the experimental rotational strengths is clearly better for computed
enantiomer A (red) than for computed enantiomer B (blue). Such quantitative analyses supplement visual matching of measured and simulated VCD spectra.
4024 S. S. Wesolowski, D. E. Pivonka / Bioorg. Med. Chem. Lett. 23 (2013) 4019–4025automation or guided navigation of steps like Boltzmann weighting
and line broadening of the composite simulated spectra such that
many aspects of in-house software may be superseded.
Metrics of ﬁt and conﬁdence level of assignment. Since VCD chiral
assignments rely upon comparisons to simulated spectra, an
assessment of the quality of the ﬁt is essential. This is an active
area of research among both academics and commercial vendors.
Perhaps the most straightforward approach is that of Stephens
who correlated the measured and computed rotational strengths
(proportional to VCD intensity) for the spectra as illustrated in Fig-
ure 11.28 More sophisticated mathematical ﬁts of the measured
and simulated ﬁngerprint region are under investigation and will
likely continue to produce additional metrics of ‘goodness of ﬁt’
and thus a quantitative conﬁdence level of assignment. Kuppens
et al. introduced the notion of using overlap integrals as the basis
for a similarity index37 and further advances in VCD neighborhood
similarity and enantiomeric similarity indices have been pub-
lished38 and implemented in commercial software (e.g., CompareV-
OA™).39 Such metrics may be converted into a conﬁdence level of
correct prediction and may be compared to databases of com-
pounds with known absolute stereochemistry. The ﬁeld is moving
toward the development of a VCD analog to the Flack parameter
commonly used in X-ray crystallography.40 In our experience,
spectra lacking peak-to-peak matching should be further interro-
gated (e.g., assessment of sample purity, potential for hydrogen-
bonded complexes, completeness of basis sets and DFT functional
employed in the simulations, etc.). While not all assignments have
been subsequently validated using X-ray analysis or stereo-speciﬁc
synthesis, all samples for which complementary data have become
available have been consistent with our VCD assignments. Any
deviation from such a track record would naturally erode the con-
ﬁdence chemists would have in this technique.
Accessibility and acceptance. As pharmaceutical companies be-
come more nimble and venture into partnerships with third par-
ties, VCD has also become accessible via relationships with
universities and companies with expertise in this area. For exam-
ple, BioTools, Inc. and other companies offer fee-for-service chiralassignment that may be a practical option for pharmaceutical com-
panies lacking in-house instrumentation or expertise. Particularly
as candidate drugs are advanced, conﬁrmation of absolute stereo-
chemistry using a complementary technique is a sound invest-
ment. Furthermore, the FDA has now recognized VCD as an
acceptable method for assignment of absolute stereochemistry.
As recently as 5 years ago, the inherent complexity of the VCD
experiment and the quantum mechanics simulations placed this
technology only in the hands of relatively few academics and
industrial groups that happened to enjoy signiﬁcant expertise in
both experimental vibrational spectroscopy and theoretical quan-
tum chemistry. X-ray crystallography, optical rotation, and elec-
tronic circular dichroism all will continue to serve as important
and complementary techniques for assignment of absolute stereo-
chemistry—indeed, the conﬁdence of the assignment increases
when independent techniques converge on the same conclusion.
The wealth and density of peaks generally present in a VCD spec-
trum matched with high-level simulations provides an elegant
means of assigning stereochemistry with high ﬁdelity. With
increasingly vibrant interactions between industry and academia
as well as close ties to vendors of VCD instrumentation and quan-
tum chemistry software packages, this technology is rapidly com-
ing of age as a mainstream tool in the arsenal of pharmaceutical
research.
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